Immunity to covid-19 could disappear in months, a new study suggests
The lowdown: Immunity to covid-19 may be short-lived, according to a new longitudinal study of people who have caught the disease and recovered.
The study: Researchers at King’s College London repeatedly tested 96 patients and health-care workers at Guy’s and St Thomas’ NHS Foundation Trust for antibodies between March and June. All the participants were confirmed to have had covid-19, either via a PCR test or a positive antibody test. The researchers found that levels of virus-fighting antibodies peaked about three weeks after symptoms started and then rapidly fell away. Although 60% of participants produced a “potent” antibody response while they had covid-19, only 17% had the same level of potency at the end of the three-month testing period. Antibody levels were higher and longer-lasting in people who had had more severe cases of covid-19. For some milder cases, it was impossible to detect any antibodies at all at the end of the three months. The research is published in a preprint paper in medRxiv, which means the findings have yet to be subjected to peer review.
What it means: The study raises the prospect that, like other coronaviruses, covid-19 could reinfect people repeatedly. If that’s the case, “herd immunity” may never arrive, either through a one-shot vaccine or through community spread of the virus, as any protective antibodies would wane with time. However, antibodies are not the only way people can fight off covid-19. T cells, which seek and destroy cells infected with SARS-CoV-2, could also provide some protection. In short, we have not yet generated enough data from patients to be able to draw conclusions on immunity with a high degree of certainty. There have been anecdotal reports of people catching covid-19 for a second time, but none have been confirmed.
Deep Dive
Biotechnology and health
What’s next for MDMA
The FDA is poised to approve the notorious party drug as a therapy. Here’s what it means, and where similar drugs stand in the US.
Beyond Neuralink: Meet the other companies developing brain-computer interfaces
Companies like Synchron, Paradromics, and Precision Neuroscience are also racing to develop brain implants
My biotech plants are dead
Two ‘Firefly petunias’ perished in a shipping misadventure, but other customers have had better luck.
The effort to make a breakthrough cancer therapy cheaper
CAR-T cells could revolutionize the treatment of a wide variety of diseases, if only we can make them cheaper.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.